drugset / Trial / NCT00777049
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the benefit of oral panobinostat monotherapy given to women with HER2-negative locally recurrent or metastatic breast cancer.
Timeline
- Start
- 2009-02
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 40 mg | Oral |